Frontiers in oncology · 2026
Bibliometric and clinical trial landscape of hepatoblastoma (2000-2024): a multi-database analysis of global research.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Xu, Lou Junyi, Li Xiaoyu, Tang Shibo, Li Shuang, Luo Zining, Xie Jiebin
Аннотация
BACKGROUND: Hepatoblastoma (HB) is the most common childhood liver malignancy, yet its research trajectory and trial landscape remain uncharacterized.
METHODS: We analyzed 219 trials from 16 international registries and 2,635 PubMed publications (2005-2024) using joinpoint regression, Gini coefficient, and diversity indices.
RESULTS: Trial activity peaked in 2013 and 2016, driven by risk-stratified protocols and the emergence of targeted therapies. Phase III/IV trials were scarce. Cisplatin dominated drug utilization, with 54-80% resistance after 4-5 cycles. Targets concentrated on VEGFR/TOP1/RET/BRAF, while Hippo/YAP and immune checkpoints were underrepresented despite mechanistic relevance. AFP (n=607), CTNNB1 (>80% mutation frequency), TP53, AKT1, and MYC were top-reported genes. Geographic inequality correlated with healthcare infrastructure rather than disease burden.
CONCLUSIONS: The HB research ecosystem exhibits robust early-phase activity but constrained late-stage validation, narrow target diversity, and geographic inequity. Multi-omics integration and pediatric-specific preclinical platforms are urgently needed to bridge translational gaps.
METHODS: We analyzed 219 trials from 16 international registries and 2,635 PubMed publications (2005-2024) using joinpoint regression, Gini coefficient, and diversity indices.
RESULTS: Trial activity peaked in 2013 and 2016, driven by risk-stratified protocols and the emergence of targeted therapies. Phase III/IV trials were scarce. Cisplatin dominated drug utilization, with 54-80% resistance after 4-5 cycles. Targets concentrated on VEGFR/TOP1/RET/BRAF, while Hippo/YAP and immune checkpoints were underrepresented despite mechanistic relevance. AFP (n=607), CTNNB1 (>80% mutation frequency), TP53, AKT1, and MYC were top-reported genes. Geographic inequality correlated with healthcare infrastructure rather than disease burden.
CONCLUSIONS: The HB research ecosystem exhibits robust early-phase activity but constrained late-stage validation, narrow target diversity, and geographic inequity. Multi-omics integration and pediatric-specific preclinical platforms are urgently needed to bridge translational gaps.